Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray–Based Assessment of Outcome
Christopher B. Moeder, Jennifer Margaret Giltnane, Malini Harigopal et al. · Journal of Clinical Oncology · 2007
PURPOSE: The variability in scoring of immunohistochemistry, whether a result of true heterogeneity or artifacts in preparation, has led to decreased reliability in companion diagnostics and the recommendation for new standards (eg, the American Society of Clinical Oncology/College of American Pathologists [ASCO-CAP] guidelines). The basis of this problem is the amount of tissue required to be representative of an entire tumor. Because protein expression on tissue microarrays (TMAs) can be rigorously measured and one 0.6-mm spot is equivalent to two to three high-power fields, we used TMAs to assess levels of heterogeneity and to determine optimal representation as a function of outcome. PATIENTS AND METHODS: We analyzed estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER-2) expression in two cohorts (n = 676 and n = 152) on a series of four to five separate TMA cores and assessed heterogeneity by linear regression analysis. Minimum, average, and maximum scores were generated for each set, which were then assessed for prognostic and predictive value. RESULTS: Each marker shows some heterogeneity, but average r values between 0.7 and 0.8 are seen between TMA spots. Analysis for prognostic value shows that the highest maximum score (of five spots) is the most prognostic for ER, whereas a high HER-2 minimum score is most prognostic for poor outcome and most predictive of response to trastuzumab. CONCLUSION: These results suggest that the representivity required for each biomarker may be a function of its role in tumorigenesis. Furthermore, these results provide scientific basis for the ASCO-CAP guidelines for assessment of HER-2 expression but perhaps suggest that the 30% figure is still too conservative.
Cited by 108 works. doi:10.1200/jco.2007.12.8033 Open-access PDF
Authors
- Christopher B. Moeder
- Jennifer Margaret Giltnane
- Malini Harigopal
- Annette M. Molinaro
- Andrew George Robinson
- Karen A. Gelmon
- David D. Huntsman
- Robert L. Camp
- David L. Rimm
References
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
- Validation of Tissue Microarray Technology in Breast Carcinoma
- Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project Experience
- Automated subcellular localization and quantification of protein expression in tissue microarrays
- Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831
- Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical Endpoints
- Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis
- Lineage dependency and lineage-survival oncogenes in human cancer
- Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome.
- Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS* Study